Ciechanover Isaac E. 4

4 · Atara Biotherapeutics, Inc. · Filed May 31, 2019

Form 4

Period: 2019-05-29

DirectorChief Executive Officer

Transactions

Sale
Common Stock
2019-05-29$22.85/sh−2,200$50,270→ 294,337 total(indirect: See footnote)
Sale
Common Stock
2019-05-29$23.30/sh−725$16,893→ 293,612 total(indirect: See footnote)
Sale
Common Stock
2019-05-30$22.72/sh−1,425$32,376→ 292,187 total(indirect: See footnote)
Sale
Common Stock
2019-05-30$23.70/sh−1,500$35,550→ 290,687 total(indirect: See footnote)

Holdings

Footnotes (6)

[F1]Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
[F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
[F4]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F5]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F6]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Documents

1 file